Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, 24 Months Study in Patients With Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease to Investigate the Safety, Tolerability and Immune Response of Repeated Subcutaneous Injections of ABvac40
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2024
Price :
$35
*
At a glance
- Drugs ABvac 40 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Araclon Biotech
- 24 Oct 2023 According to an Araclon Biotech media release, Merce Boada Rovira, M.D., Ph.D is the principal investigator of this study.
- 24 Oct 2023 Primary endpoint (Immune response) has been met, according to an Araclon Biotech media release.
- 24 Oct 2023 According to an Araclon Biotech media release, data from this study were presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.